Abstract
In this issue of Blood, Dombret et al1 report the final analysis of the international phase 3 study of azacitidine vs conventional care regimens in older (≥65 years), newly diagnosed acute myeloid leukemia (AML) patients with >30% bone marrow blasts and white blood cell (WBC) counts ≤15 × 109/L (AZA-AML-001 study).
Cite
CITATION STYLE
APA
Huls, G. (2015, July 16). Azacitidine in AML: A treatment option? Blood. American Society of Hematology. https://doi.org/10.1182/blood-2015-06-648071
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free